Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Dabur Q4 profit jumps...

    Dabur Q4 profit jumps 19 percent to Rs 397 crore

    Written by Ruby Khatun Khatun Published On 2018-05-02T10:15:21+05:30  |  Updated On 2 May 2018 10:15 AM IST
    Dabur Q4 profit jumps 19 percent to Rs 397 crore

    New Delhi: FMCG major Dabur India reported a 19.04 percent increase in consolidated net profit at Rs 397.18 crore for the fourth quarter ended March 2018 on strong volume growth and rise in operating margin.


    The company had posted a net profit of Rs 333.65 crore in the January-March period a year ago, Dabur India said in a BSE filing.



    Total income during the quarter under review grew 6.38 percent to Rs 2,106.15 crore, against Rs 1,979.72 crore in the corresponding quarter a year ago.

    "We have delivered another strong performance in the quarter with our India operating margin touching a historical high of 27.2 percent. Our operating margin has increased on the back of improved operating efficiencies and judicious cost management," said Dabur India CEO Sunil Duggal.


    Dabur's total Q4/FY2017-18 expenses were up 3.56 percent to Rs 1,603.56 crore as against Rs 1,548.32 crore.


    "The domestic FMCG business reported an underlying volume growth of 7.7 percent during the quarter," Dabur India said in a statement.


    Its revenue from consumer care business was up 8.16 percent to Rs 1,677.43 crore in the fourth quarter of FY 2017-18 as against Rs 1,550.84 crore in the corresponding quarter a year ago.


    Its revenue from food business was down 1.54 percent to Rs 293.40 crore as against Rs 298.01 crore in the corresponding period of the previous fiscal.


    Retail business was also down 9.33 percent to Rs 27.89 crore during the quarter as against Rs 30.76 crore. The other segment was also down 15.39 percent to Rs 24.84 crore as against Rs 29.36 crore.


    Dabur's international sales in January-April period were up 16.8 percent in constant currency terms.


    "Sales in GCC markets grew 51 percent led by Saudi Arabia which reported an 82 percent growth during the quarter. The Business in Egypt reported a 38 percent growth while sales in Nepal grew by around 19 percent," it added.


    For the financial year 2017-18, net profit was up 6.04 percent to Rs 1,357.74 crore as against Rs 1,280.31 crore in FY 2016-17.


    Its total income was at Rs 8,053.52 crore, marginally up to 0.67 percent in 2017-18 as against Rs 7,999.79 crore in the previous fiscal.


    Dabur has also recommended 625 percent dividend, which is Rs 6.25 per equity share having a face value of Re 1 each for the financial year 2017-18.


    "The board of directors today recommended a dividend of 625 percent, which includes a final Dividend of 125 percent and a one-time special dividend of 500 percent. This brings the Total Dividend for the year to 750 percent," the company said.

    DaburDabur IndiadividendFinancial resultsFMCG businessnet profitprofitQ4revenueSunil Duggal
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok